An international expert panel discusses POCT related to COVID-19 severity assessment and risk prediction, plus covers the role of POCT in antimicrobial resistance during the pandemic, in this video seminar originally delivered live on 4 September 2020. Hear from Professor Nicholas Francis (UK), Professor Ivan Gentile (Italy), Dr Carl Llor (Spain), Professor Dag Berild (Norway) and Dr Aggy York (UK) by clicking here.
Hear expert opinion on the use of CRP POCT for COVID-19 management and reduction of antimicrobial resistance
This on-demand seminar recording features expert panel discussion on the importance of C-reactive protein (CRP) point-of-care testing (POCT) related to COVID-19.
The seminar presents studies from around the world indicating that CRP levels are a valuable inflammatory marker for severity and risk assessment in COVID-19 patients.
The session also covers the importance of antibiotic stewardship programmes in the context of the global pandemic and looks at the recent findings from the PACE study, which investigated CRP POCT as a guide for antibiotic prescribing in acutely exacerbated chronic obstructive pulmonary disease (COPD).
See below for a list of our renowned expert panel and a summary of the programme:
- Professor Nicholas Francis (UK)
- Professor Ivan Gentile (Italy)
- Speaker: Severity assessment and outcome prediction in the COVID-19 patients
- Dr Carl Llor
- Speaker: The emergence of multi-resistance associated with the overuse of antibiotics during COVID-19 pandemic
- Professor Dag Berild (Norway)
- Speaker: Antimicrobial stewardship in the time of COVID-19 is vital – AMR still persists and could be heightened by the pandemic
- Dr Aggy York (UK)
To read the learning objectives for this session, plus watch the seminar in full, please click here.
The views and opinions presented are of the author only. The content contained in this webcast is intended for informational / educational purposes only.
&copia; 2022 Abate. Tutti i diritti riservati. Tutti i marchi citati sono marchi del gruppo di società Abbott o dei rispettivi proprietari.